Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant

Rebecca L. Williams-Karnesky* and Mary P. Stenzel-Poore

Department of Molecular Microbiology and Immunology, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA

Abstract: Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the potential use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to developing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune responses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic neuroprotectant.

Key Words: Adenosine, adenosine receptors, cerebral ischemia, neuroprotection, preconditioning, stroke, treatment.

INTRODUCTION

Ischemia occurs when blood flow to an organ is inhibited, resulting in a lack of delivery of oxygen and nutrients, and a decreased clearance of potentially toxic metabolic waste products. The brain is selectively vulnerable to ischemia, as it does not store glycogen but instead relies on glucose from the blood. The major strategies used to treat stroke focus on the re-establishment of blood flow to affected tissue. This process of reperfusion has the potential to increase damage to ischemic tissue by generating oxygen-derived free radicals. Thus, it is essential to develop therapies that target both ischemic and reperfusion-related injury in stroke.

Cerebral ischemia is one of the leading causes of morbidity and mortality in the United States. Each year, more than 780,000 individuals suffer from a stroke [94], 87% of which are ischemic [53]. In addition to stroke, brain ischemia and reperfusion (IR) injury can be caused by cardiac arrest. In fact, brain injury affects at least 1/3 of individuals who survive a heart attack [93]. Development of novel drugs for cerebral ischemic injury is a necessity. Many instances of stroke are predictable; as many as 0.7% of all surgery patients will suffer from surgery-associated brain ischemia [55], while 10% of patients undergoing cardiac or vascular surgeries will suffer from a frank stroke during or after surgery [11, 15, 40, 55, 69, 76]. Prophylactic neuroprotection has emerged as a promising field of study. Adenosine, an endogenous purine nucleoside that modulates many physiological processes and its receptors have shown great promise as therapeutic targets in the reduction of damage following experimental stroke. In addition to their value as post-stroke treatments that reduce the extent of stroke damage, these compounds are prime candidates for prophylactic neuroprotection.

BRIEF HISTORY OF ADENOSINE-BASED THERAPIES IN STROKE

For some time adenosine and its receptors have been viewed as potential therapeutic targets for the treatment of stroke. In practice, however, adenosine-based therapies for the treatment of stroke have proven complex in their implementation [107]. Difficulties stem from the widespread distribution of adenosine receptors within the central nervous system (CNS) and throughout the body. For this reason, even direct targeting of specific adenosine receptors leads to widespread off-target effects. Further complications in developing robust adenosine-based therapeutics include imperfect targeting of specific receptor subtypes by agonists and antagonists. Finally, stroke is comprised of a complex set of pathophysiological processes that are influenced differentially by adenosine spatially and temporally.

BASIC PHYSIOLOGY OF ADENOSINE AND ITS RECEPTORS

The adenosine receptor family consists of four members: A1, A2A, A2B and A3 receptors. Adenosine receptors consist of seven transmembrane spanning regions, and are coupled to G proteins, which activate a number of intracellular signaling pathways [45]. Adenosine receptors are broadly grouped into two categories: A1 and A3 receptors, which couple to inhibitory G proteins, and A2A and A2B receptors, which couple to stimulatory G proteins. However, adenosine receptors are pleiotropic; they can couple with various G

*Address correspondence to this author at Department of Molecular Microbiology and Immunology, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA; Tel: 503-494-5312; E-mail: williarc@ohsu.edu

©2009 Bentham Science Publishers Ltd.
proteins and transduction systems according to their degree of activation and their particular cellular or subcellular location [24].

Extracellular adenosine levels are low under normal conditions, but increase substantially in response to metabolic stress [10, 29, 45]. Extracellular adenosine levels are increased under stress via several mechanisms: 1) inhibition of equilibrative nucleoside transporters, 2) increased release of ATP from cells and stimulation of extracellular breakdown of ATP by ectonucleotidases, and 3) inhibition of intracellular adenosine removal [10, 29]. Rapid elevations in adenosine occur following ischemia in vitro such that within 10 minutes of ischemia adenosine levels in hippocampal slices are increased by more than 20μM [82]. In vivo studies also show increases in adenosine in the CNS with cerebral ischemia [61]. For a more thorough discussion of the source of adenosine in ischemia and in epilepsy, please see Frenguelli & Dale, this issue. Interestingly, increased levels of adenosine during stroke are not limited to the CNS, as adenosine levels in serum have also been shown to increase following transient ischemic attack (TIA) and stroke in humans [62].

THE EFFECTS OF ADENOSINE RELEASE ON THE CNS DURING STROKE

Adenosine is a potent endogenous neuromodulator with known neuroprotective properties [23, 37, 91]. Administration of adenosine to the brain at the time of stroke ameliorates damage [57]. Further, transgenic overexpression of adenosine kinase, the primary negative enzymatic regulator of adenosine, leads to increased vulnerability to ischemic cell death, presumably due to decreased levels of adenosine in the CNS [85]. In practice, however, the clinical use of adenosine as a neuroprotectant during stroke has been unsuccessful. Adenosine is an imperfect neuroprotectant, as it can provide benefit in some cases and exacerbate tissue damage in others [23, 84]. Adenosine receptors are distributed throughout the body, and play a prominent role in cardiac and renal system function. When administered intravenously, adenosine at bolus doses of 6-12mg is used to treat patients with paroxysmal supraventricular tachycardia to restore normal sinus rhythm by slowing conduction through the A-V node in the heart [32]. At higher doses, adenosine causes decreased blood pressure by decreasing vascular resistance. Adenosine is also a respiratory stimulant, and intravenous administration can increase ventilation and reduce arterial PCO₂ causing respiratory alkalosis. Decreased blood flow and respiration compound cerebral ischemic injury, superseding the potential neuroprotective properties of systemically administered adenosine.

Targeted delivery of adenosine to the CNS in a controlled manner has also proven problematic. Adenosine has a very short half-life in human plasma (<5 seconds), and low blood brain barrier permeability [81]. Molecules with greater plasma stability have been tested such as adenosine analogs, receptor-specific agonists and antagonists, and enzymatic regulators of adenosine. Pretreatment with the unspecified adenosine agonist NECA (adenosine-5′-N-ethylcarboxamide) protects human astrocytoma cells from apoptosis under hypoxic conditions in vitro [8]. Success has also been reported with adenosine agonists in rodent models of cerebral ischemia. Systemic administration of the adenosine kinase inhibitor GP683 at a moderate, but not high or low dose, to rats within 270 minutes of onset of surgical ischemia significantly reduces cerebral damage [104].

Unfortunately, the optimal window of administration for adenosine-modulating drugs has been difficult to determine. This is a common problem encountered by many potential stroke therapeutics that show promise in animal models, as accurate determination of the time of stroke onset is difficult in human patients. Stroke patients routinely face delays in access to clinical care, often due to a failure to recognize stroke symptoms. The mean hospital arrival time for patients suffering from stroke is approximately 11 hours after the onset of vessel obstruction [4]. Once patients have been admitted to the hospital, more time may elapse before accurate diagnosis and treatment begins. Thus, stroke drugs with long time windows of efficacy are most desirable. In the case of adenosine, there is the added complication of a diverse distribution of adenosine receptors in the brain, whose actions can be opposing, either spatial or temporally. While administration of a specific adenosine receptor agonist early on may be protective, administration of the same drug late in the course of stroke may exacerbate ischemic damage.

Direct administration of adenosine-modulating drugs to the CNS is used in animal models to dissect the systemic and CNS effects of adenosine in stroke. These targeted experimental therapies have shown efficacy in reducing ischemic damage in small animal models of stroke. Intracerebral ventricular (ICV) administration of the selective A₁R agonist CI-IB-MECA (2-chloro-N6-(3-iodobenzyl) adenosine-5′-N-methylcarboxamide) decreases infarct volume in a mouse model of transient ischemia [18]. Clinically, ICV administration of drugs is impractical and the uncertainty about the diverse temporal effects of adenosine receptor activation and blockade remains problematic. While animal experiments using ICV administration might not translate directly into clinical therapies, they provide insight into the local temporal effects of adenosine on the CNS. The specific functions of the adenosine receptors in the CNS in stroke have been further illuminated by the development of increasingly selective adenosine receptor agonists and antagonists and the creation of mice with targeted deletions in the adenosine receptor system (Table I).

A₁R Effects in the CNS

In the brain, the A₁ subgroup is the most abundant and widespread of the adenosine receptors [24]. A₁ receptors have the highest affinity for adenosine of all the subtypes [29]. Under basal conditions, adenosine likely acts primarily via this receptor subtype. Based on immunohistochemical studies, A₁ receptor expression has been shown to be high in the hippocampus, cerebral cortex, basal ganglia, and some thalamic nuclei in humans and a variety of animals. A₁ receptor expression is highest in neurons, but the receptor is also present on astrocytes, microglia, and oligodendrocytes [24]. A₁ receptors are a central focus in the study of the neuroprotective role of adenosine in stroke due to their high concentration and affinity for adenosine, known coupling to inhibitory G proteins and the large number of selective agonists and antagonists available for use.
Adenosine and Stroke

Table 1. Effects of Adenosine on Cerebral Ischemia: Studies with Transgenic Animals

| Target                       | Manipulation              | Model         | Effect                                                                 | Reference |
|------------------------------|---------------------------|---------------|------------------------------------------------------------------------|-----------|
| Adenosine kinase             | Overexpression in brain   | tMCAO*        | 3-fold increase in infarct volume vs. wildtype controls<sup>b</sup>     | [85]      |
| A<sub>1</sub>R               | Global Knockout           | Global Ischemia | No change in percentage dead neurons vs. wildtype controls             | [78]      |
| A<sub>2A</sub>R              | Global Knockout           | tMCAO         | Reduction in infarct volume vs. wildtype controls                      | [20]      |
| A<sub>2A</sub>R              | Bone Marrow Chimera       | tMCAO         | WT BMDCs→KO: ~20% decrease in infarct volume, not statistically significant<sup>c</sup>  
KO BMDCs→WT: ~30% reduction in infarct volume, improved neurological outcome  
KO BMDCs→KO: ~60% decrease in infarct volume | [117]     |
| A<sub>1</sub>R               | Global Knockout           | tMCAO ligation | Increased infarct volume vs. wildtype controls                        | [18]      |

<sup>a</sup>MCAO: transient middle cerebral artery occlusion  
<sup>b</sup>MCAO given for 15 minutes. 60 minute occlusion was lethal in ADK overexpressing animals.  
<sup>c</sup>All animals versus WT BMDCs→WT.

Activation of A<sub>1</sub>R receptors is generally considered protective in the context of noxious stimuli. The brain uses vast amounts of ATP generated by oxidative phosphorylation to maintain control of K<sup>+</sup> and Na<sup>+</sup> gradients in neurons. Function of the Na<sup>+</sup>/K<sup>+</sup> ATPase is disrupted during ischemia because mitochondria are unable to make ATP when glucose and oxygen levels are low. Altered Na<sup>+</sup>/K<sup>+</sup> ATPase activity leads to depolarization of the neuronal plasma membrane and subsequent release of excitatory neurotransmitters. As a result, calcium-permeable NMDA channels open causing calcium-mediated cell death. For a more complete review of excitotoxic cell death in stroke, please see Doyle K. P. et al., 2008 [28]. A<sub>1</sub>R receptors are linked to inhibitory G proteins, which inhibit adenyl cyclase, activate inward rectifying K<sup>+</sup> channels, inhibit Ca<sup>2+</sup> channels, and activate phospholipase C [10]. This has the cumulative effect of decreasing neuronal excitability. Activation of A<sub>1</sub>R receptors also leads to feedback inhibition of release of presynaptic excitatory neurotransmitters, such as glutamate. Stimulation of A<sub>1</sub>R receptors can therefore lead to prevention of excitotoxic cell death under ischemic conditions.

In practice, A<sub>1</sub>R receptor activation has been shown to produce conflicting effects in both in vivo and in vitro models of cerebral ischemia. As neurons in the CA1 region of the hippocampus are particularly susceptible to hypoxic cell death, this region is often used as an indicator of tissue damage in both in vitro and in vivo models of ischemia. In hippocampal slice preparations recovery from hypoxia, as measured by recovery of field EPSP (fEPSP) in the CA1 region, was attenuated by the application of the A<sub>1</sub>R antagonist DPCPX (1,3-dipropyl-8-cyclopentylxanthine) [97]. This result would suggest that antagonists of A<sub>1</sub>R have a detrimental effect in hypoxia, at least at the neuronal level. However, application of the A<sub>1</sub>R antagonist 8-CPT (8-cyclopentyl theophylline) to hippocampal slices at the time of insult does not exacerbate hypoxia induced cell death in the CA1 region of hippocampus [78]. Hippocampal slices from A<sub>1</sub>R knockout mice subjected to hypoxia show a small, though not statistically significant decrease in damage to neurons in the CA1 region [78]. A<sub>1</sub>R knockout mice, when exposed to global ischemia, show no increased neuronal damage in the CA1 region of the hippocampus, the cortex, or the striatum as compared to wildtype controls [78]. Mice treated with 8-CPT at the time of global ischemia have a significant increase in cell death in the CA1 region, the cortex and the striatum when compared to control-treated animals. Taken together, these results suggest that the protective effects of A<sub>1</sub>R activation are temporally regulated. Perhaps acute stimulation via A<sub>1</sub>R receptors provides protection by decreasing synaptic transmission, but during recovery ischemia-induced down-regulation of A<sub>1</sub>R receptors may be beneficial.

A<sub>2A</sub>R Effects in the CNS

A<sub>2A</sub>R receptors are also distributed widely throughout the brain. However, they are expressed at lower density in most regions than A<sub>1</sub>R receptors [24]. The highest density of A<sub>2A</sub>R receptors can be found in the striatum [29]. The affinity of A<sub>2A</sub>R receptors for adenosine is also relatively high. The advent of more selective A<sub>2A</sub>R receptor agonists and antagonists, and the generation of A<sub>2A</sub>R knockout mice, has revealed an important role of A<sub>2A</sub>R receptors as mediators of neuroprotection in stroke. Because they are coupled to excitatory G proteins, it would seem that stimulation of A<sub>2A</sub>R receptors would exacerbate ischemic damage. Paradoxically when applied centrally, A<sub>2A</sub>R receptor antagonists afford protection in several in vivo models of ischemic injury [38, 70, 72, 83, 108]. Further, A<sub>2A</sub>R receptor knockout animals show a significant decrease in damage following focal cerebral ischemia [20]. The location of A<sub>2A</sub>R receptors in the brain may also influence ischemic injury. In a model of permanent focal ischemia, a decrease in A<sub>2A</sub>R receptor ligand affinity and an increase in receptor expression were seen in the striatum, but not the cortex [105]. Stroke can occur in diverse regions of the brain depending on the specific vessels involved. It may be possi-
ble to tailor adenosine receptor modulating drugs to patients based on the area of ischemia as more is learned about the location specific properties of adenosine receptors. Perhaps A2A receptor antagonism would be a more potent therapy than for patients with striatal strokes than those with primarily cortical injury.

Surprisingly, peripheral stimulation of A2A receptors has also been shown to provide protection to cerebral ischemia in vivo [98, 108]. Systemic administration of A2A receptor agonists protect against spinal chord ischemia-reperfusion and traumatic spinal chord injury in vivo [17, 89]. Direct administration of A2A receptor agonists to the brain immediately preceding intracerebral hemorrhage reduce cell death [68]. In these cases, protection afforded by A2A receptor agonists is attributed to a reduction of neutrophil infiltration into the affected tissue. Stimulation of A2A receptors has been shown to decrease production of proinflammatory cytokines by peripheral immune cells [14, 64], which may play a role in exacerbating injury in the CNS. However, elucidation of the distinct contributions of A2A receptors in the CNS and in the periphery to ischemic damage has proven difficult.

A2AR knockout bone marrow chimera mice have been created to separately address the peripheral and CNS effects of A2A receptors. As stated previously, A2AR knockout mice are protected from cerebral ischemic damage [20]. Similarly, A2AR knockout mice are protected from compression injury of the spinal chord when compared to wild-type controls [63]. Chimeric mice lacking A2A receptors in non Bone Marrow Derived Cells (BMDCs) also show protection from compression, but only a small reduction in damage due to infarct is seen in these mice. Notably, protection in spinal compression injury is abolished in wild-type/knockout bone marrow chimera mice that lack the A2A receptor in BMDCs but is retained in cerebral ischemia [20, 63]. Interestingly, the amelioration of damage in chimeric mice lacking A2A receptors on BMDCs is not as robust as in global A2A knockout animals. These results suggest that neuroprotection in these two models of injury may be mediated differentially. In the case of ischemic injury, over 90% of the microglia in the damaged area of chimeric mice were found to be brain derived, indicating that suppression of inflammation in peripheral BMDCs may not have been significant in this circumstance [20]. A2A receptor activation may be beneficial acutely in the periphery by acting on brain endothelium to increase cerebral blood flow and by reducing inflammatory cytokine production by immune cells, while A2A receptor antagonism may be beneficial in the CNS during later stages of ischemia, when prolonged activation of neurons could be detrimental. For a more thorough discussion of A2A receptors as a target for neuroprotection, please see Roderigo et al., this issue. Additionally, A2A receptor pharmacology is discussed in more detail in the review by Shen et al., also in this issue.

A2B Receptor Effects in the CNS

The effects of adenosine A2B receptors during ischemia are not as well characterized as those of A2A receptors. A2B receptors are perhaps the least studied member of the adenosine receptor family. A2B receptors are present on vascular smooth muscle and endothelial cells, as well as on astrocytes [34, 54]. Due to their low affinity for adenosine, and their relative paucity in the brain, A2B receptors seem to be activated only under hypoxic or ischemic conditions, when levels of adenosine surge [59, 92]. Recent in vitro studies have suggested a role for A2B receptors in production of glial cell line-derivate neurotrophic factor (GDNF) by astrocytes [114]. Adenovirus-mediated GDNF pretreatment has been shown to reduce cell death following Middle Cerebral Artery Occlusion (MCAO) by both intracerebral and systemic administration [48, 58]. Intracerebral infusion of GDNF post-MCAO increases striatal neurogenesis in rat, indicating a possible role in regeneration as well as protection [60]. A2B receptors may also regulate vascular leak during hypoxia [30], potentially contributing to increased blood flow to affect tissues. Studies of si-RNA mediated A2B receptor suppression in vitro have shown increased endothelial leak in response to hypoxia, and A2B receptor knockout animals show increased vascular permeability as compared to wild-type or other adenosine receptor knockout animals [30]. The ablation of the A2B receptor in mice leads to a basal level of low-grade inflammation and increased leukocyte adhesion to the vasculature [115]. A2B receptor mice also display an enhanced expression of pro-inflammatory cytokines as compared to control mice. Bone marrow transplantation studies indicate that these processes are regulated primarily by bone marrow, and to a lesser extent vascular, A2B receptors [115]. Taken together, these results indicated that A2B receptors might afford protection to the CNS when activated under ischemic conditions, either directly or by decreasing inflammation and reducing immune cell adhesion to vascular endothelium.

A3 Receptor Effects in the CNS

A3 receptors stimulate inhibitory G proteins. Like A1 receptors, A3 receptor activation inhibits adenylyl cyclase and leads to the activation of phospholipase C. However, the affinity of A3 receptors for adenosine is the lowest of all subgroups, on the order of 6500 nM, which is roughly 100 times lower than the affinity of A1 receptors [29]. A3 receptors are found throughout the brain, though they are present at levels 10-30 fold lower than A1 or A2 receptors [107]. Interestingly, A3 receptors on CNS cells have been shown to be involved in both cell survival and death, depending on the degree of receptor activation and the specific pathophysiological conditions [1]. More specifically, long duration activation of A3 receptors leads to cell death via necrosis or apoptosis, while short-term stimulation of central A3 receptors prior to injury may reduce spontaneous apoptosis [109]. Application of A3 receptor antagonists to hippocampal slices during prolonged oxygen-glucose deprivation (OGD) prevents neuronal loss in the CA1 region [87]. Interestingly, during brief periods of OGD, A3 receptors antagonism resulted in faster recovery of fEPSP, indicating an inhibitory role of these receptors during initial hypoxia [87]. Chronic pre-exposure to A3 agonist is protective in vivo; this may be due to rapid desensitization of A3 receptors [80, 106]. Intravenous or ICV administration of the selective A3 receptor agonist CI-1B-MECA 165 minutes and 15 minutes prior to the onset of transient ischemia is protective in rats [18]. Consistent with these results, A3 knockout animals have increased susceptibility to transient cerebral ischemic injury [18].
ischemic administration of Cl-IB-MECA is also protective in vivo [110]. Interestingly, in contrast to in vitro results, a single dose of Cl-IB-MECA given acutely during focal ischemia increased infarct volume [109]. These results suggest that the effects of \( A_3 \) receptor signaling during ischemic injury may be beneficial or detrimental depending on the specific circumstances in which the stimulus occurs. Correctly timed, \( A_3 \) receptor modulation may be a potential target for therapeutic intervention. Early chronic stimulation of \( A_3 \) receptors leading to their down regulation, or acute \( A_3 \) receptor blockade, may be one strategy for inducing prophylactic neuroprotection in advance of predicted ischemic injury.

**PAST COMPLICATIONS IN DEVELOPING ADENOSINE-BASED THERAPIES FOR STROKE**

A major stumbling block in the development of adenosine-based neuroprotective strategies has been the dramatic systemic effects of adenosine which include decreased heart rate, blood pressure and body temperature, and sedation [9]. As more specific adenosine receptor agonists and antagonists are developed, drugs with fewer off-target effects may emerge. Novel therapeutic methods may also allow for easier local delivery of adenosine, or modulators of specific adenosine receptors, to the central nervous system. A novel example of one such strategy, the implantation of adenosine-releasing silk polymer to treat epilepsy, can be found in Wilz, A. et al., 2008 [112]. Additionally, the systemic effects of adenosine may be harnessed to ameliorate damage caused by ischemic stroke.

**PERIPHERAL IMMUNE INVOLVEMENT AND INFLAMMATORY CYTOKINES IN STROKE**

In the context of a pathogen invasion, a vigorous inflammatory response is an effective means to clear an invasive microorganism. Responding immune cells kills not only pathogens, but also the cells harboring them. However, when this same response is co-opted by the host to clear infarcted tissue, it can damage the very cells it is intending to save. Much of the damage associated with brain ischemia is due to the resultant inflammatory response. This has been demonstrated by the amelioration of ischemic damage through the use of anti-inflammatory strategies [42, 90, 99]. Inflammation following stroke originates with microglia and astrocytes, which detect injury-associated molecules and produce pro-inflammatory cytokines [31, 46]. Vascular endothelium becomes activated, signaling to the periphery and increasing blood brain barrier permeability [2, 6]. The inflammatory response is further promoted by the infiltration of macrophages and neutrophils (Fig. 1). These cells produce proteolytic enzymes, inflammatory cytokines and other cytotoxic molecules.

Pronflammatory cytokines have been implicated in exacerbating the damage in stroke by increasing neuroinflammation, with particular attention paid to TNF-\( \alpha \) [5]. TNF-\( \alpha \) is pleiotropic inflammatory cytokine that is produced by a variety of cell types, including peripheral immune cells and cells that are resident in the CNS. Intravenous administration of anti-TNF-\( \alpha \) antibody to mice following transient cerebral

![Fig. (1). Peripheral immune involvement following ischemic brain injury.](image-url)

Neurons and astrocytes damaged by ischemia release pro-inflammatory factors such as TNF-\( \alpha \) into the brain parenchyma. These pro-inflammatory molecules in turn diffuse and bind receptors on vascular endothelial cells. Activation of endothelial cells via TNF and related receptors leads to nuclear factor kappa B (NFkB) activation and nuclear translocation. In the nucleus, NFkB activity induces transcription of adhesion molecules and chemokines, including E-selectin, P-selectin, vascular cell adhesion molecule (VCAM1), intercellular adhesion molecule (ICAM1) and heparin sulfate proteoglycan. Peripheral immune cells traveling through the vasculature express receptors to adhesion molecules (i.e. PSGL-1 for selectins, \( \alpha 4\)-integrin for VCAM1). As they survey the body, leukocytes roll along the activated endothelium, adhere via adhesion molecules and become activated themselves, then extravasate into the brain parenchyma.
ischemia has been shown to ameliorate damage and reduce edema [51]. Adenosine receptor agonists and antagonists are both effective suppressors of TNF-α through their actions on various cell types. In rabbits undergoing transient spinal cord ischemia, lower levels of plasma TNF-α and decreased damage are seen following intravenous administration of the adenosine A2A analogue ATL-146e (4-(3-[6-amino-9-(5-ethylcarbamoyl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-9H-purin-2-yl)-prop-2-ynyl)-cyclohexanecarboxylic acid methyl ester) [16]. Understanding how adenosine modulates the release of TNF-α by both peripheral immune cells and by cells in the CNS may be particularly beneficial when developing adenosine based therapies for the treatment of stroke. The effects of TNF-α on adenosine receptor expression may also provide insight into the phenomenon of ischemic preconditioning, a phenomenon in which a brief noxious stimuli induce changes in the CNS and in the periphery that result in endogenous neuroprotection from stroke.

THE EFFECTS OF ADENOSINE ON THE PERIPHERAL IMMUNE SYSTEM

Adenosine may play a role in modulating systemic immune involvement in stroke that is in addition to its role in the CNS. Adenosine levels in serum increase following stroke [62]. This finding is particularly significant, as peripheral immune cells express functional adenosine receptors, and respond to changes in extracellular adenosine (Fig. 2). It is also important to consider the peripheral effects of adenosine-based therapeutics, as systemic administration of adenosine-modulating drugs affect immune cells as well as the CNS.

Effects of Adenosine on Monocytes and Macrophages

Monocytes and macrophages express the full complement of A1, A2A, A2B, and A3 receptors. Stimulation via adenosine receptors not only shapes macrophage function, but can also influence differentiation. High levels of extracellular adenosine can delay monocyte maturation [35]. Broadly, extracellular adenosine has the affect of changing the response of macrophages from proinflammatory to anti-inflammatory. Adenosine inhibits TNF-α and IL-12 production, while increasing IL-10 production by macrophages [44]. These effects appear to be primarily mediated via A2A, A2B and A3 receptors [43]. Recent results have shown that A2B receptor activation with the selective agonist BAY 60-6583 on macrophages in vitro and in vivo leads to decreased production of TNF-α following injurious stimuli [19]. However, it should be noted that adenosine has differential effects on macrophage development depending on the receptor it stimulates. Stimulation via A1 receptors has been found to influence monocytes to become phagocytic multinuclear giant cells, while stimulation via A2A and A2B receptors has been shown to inhibit this process [71]. Monocytes also affect resolution of ischemic damage by influencing vascular endothelial cells. Application of the selective A1 receptor agonist CPA (N6-cyclopentyladenosine) to macrophages results in increased production of vascular endothelial growth factor (VEGF), leading to an increase in capillary formation in vitro [22]. When activated, macrophages can themselves be a source of extracellular adenosine, via ATP production [44]. Through this local extracellular production of adenosine, macrophages may also suppress the inflammatory response of other immune cells. Monocytes and macrophages exert broad influence on damage and healing following stroke. Stimulation of the A2A receptor inhibits production of TNF-α, decreasing inflammation at the time of ischemia. Therapies that increase the expression of A2A receptors, such as the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) [102], may be useful as a prophylactic to modulate the response of macrophages to endogenous adenosine release during ischemic injury.

Effects of Adenosine on T and B Lymphocytes

Recruitment of activated lymphocytes to the brain parenchyma following stroke leads to increased tissue damage [52]. Adenosine may serve as a negative regulator of lymphocyte activation, and thereby reduce damage caused by an excessive inflammatory response. Lymphocytes express A2A, A2B and A3 adenosine receptor subtypes [39]. Similar to what is seen in macrophages, stimulation of adenosine receptors on lymphocytes has the net effect of suppressing activation. The adenosine A2A receptor has been directly implicated in adenosine-mediated suppression of cytokine production and cytotoxic activity in natural killer T cells, a highly specialized group of T lymphocytes [50]. Additionally, evidence is mounting to support the hypothesis that adenosine mediates the formation of T regulatory cells [43, 118]. Unlike cyto-

---

**Fig. (2). Adenosine modulates peripheral immune cell function.** Adenosine modulates the activity of peripheral immune cells differentially depending on the receptors that are activated. Overall, activation of A2A and A2B receptors directs immune cells to an anti-inflammatory response. This property could be harnessed in stroke to reduce inflammatory damage in the CNS caused by infiltrating activated immune cells. Stimulation via A3 receptors on immune cells tends to increase migration and activity, but also leads to angiogenesis through their interaction with cerebral vascular endothelial cells.
toxic T lymphocytes, regulatory T cells serve as suppressors of inflammation, and can limit damage to healthy tissues caused by overactivated immune cells. Surprisingly, the regulatory function of T regulatory cells has been linked to a pathway of adenosine production [25]. A2A receptor appears to be the dominant receptor subtype mediating the immunosuppressive effects of adenosine on lymphocytes. Stimulation of the A2A receptor in mixed lymphocyte populations leads to a decrease in expression of the intercellular adhesion molecule ICAM, decreased production of several proinflammatory cytokines, and decreased proliferation [103]. However, it should be noted that the actions of A2A receptor stimulation could be blocked via A1 or A3 receptor activation [103]. While this may be relevant with acute systemic administration of adenosine-based therapeutics selective for A1 and A3 agonists, the negative consequences could potentially be overcome by using short-acting, CNS-targeted drugs.

**Effects of Adenosine on Neutrophils and other Granulocytes**

Neutrophils are granulocytes, members of the polymorphonuclear family of cells, which also includes eosinophils and basophils. Following activation by cytokines and chemokines, neutrophils upregulate intracellular adhesion molecules, adhere to vascular endothelium and migrate into damaged tissue. Migration of neutrophils occurs well before migration of monocytes or lymphocytes [113]. Once at the site of inflammation, neutrophils release preformed granule constituents, lytic enzymes, reactive oxygen species, and inflammatory cytokines such as TNF-α [43]. While helpful in the context of response to infection with a pathogen, as with other immune cells, over-activation of neutrophils at sites of injury can exacerbate damage by damaging healthy tissue. Neutrophils in particular are strongly recruited following ischemia-reperfusion injury, and have been shown to contribute significantly to subsequent neuroinflammatory damage [111]. It has long been known that adenosine promotes migration of neutrophils, and it has recently come to light that this occurs via stimulation of A1 and A3 receptors [21, 95]. Conversely, by acting via A2A receptors, adenosine down regulates surface expression of adhesion molecules, and decreases the production of pro-inflammatory cytokines [43]. Application of the adenosine kinase inhibitor GP515 attenuates neutrophil degranulation via an adenosine-mediated action [12]. This action appears to be mediated strongly by A3 receptors, as well as by A2A receptors, but not by A1 receptors [12]. In mast cells, A2A receptor stimulation also blocks degranulation, while A3B receptor activation causes release of VEGF [22]. Taken together, these results indicate that A2A receptors serve as a negative regulator of granulocyte-induced inflammation, while A1 receptors may promote the inflammatory properties of these cells. A2A receptors appear to have mixed effects on neutrophils, depending on the context in which the stimulation occurs.

Neutrophils infiltrate into the brain parenchyma following ischemic injury, contributing to immune mediated inflammatory damage following stroke; adenosine receptors provide an accessible, potential target for modulation of the proinflammatory properties of these cells. Overall, A2A receptor stimulation on neutrophils acutely and immediately following stroke likely decreases inflammatory damage. Compounds that directly induce expression of A2A receptors on neutrophils such as LPS, or those that elicit the release of cytokines like TNF-α, Interleukin 1β (IL-1β) [36], may be useful as prophylactic neuroprotectants by reprogramming the response of neutrophils to stroke.

**A PUTATIVE ROLE FOR ADENOSINE IN PROPHYLACTIC NEUROPROTECTION**

It is well known that certain antecedent treatments can protect patients from damage due to an ischemic episode. Cerebral ischemic preconditioning has emerged as a promising field of study for the development of prophylactic neuroprotectants. Ischemic preconditioning can be induced by a variety of noxious stimuli, including short periods of hypoxia or ischemia, cortical spreading depression, brief seizure, exposure to inhaled anesthetic or low dose of bacterial endotoxin [27]. Preconditioning that occurs rapidly, immediately following stimulation, is termed acute preconditioning. Local increase of adenosine in the brain is likely one of the mechanisms by which acute preconditioning occurs [24]. Rapid upregulation of neuroprotective A1 receptors in the brain has been shown to be one mechanism of adenosine-mediated acute preconditioning. When given during a brief conditioning period of ischemia, the selective A1 agonist DPCPX attenuates the protective effects of acute preconditioning [3, 75]. Rapid tolerance against focal ischemia by isoflurane is also attenuated by DPCPX administration [65]. As an additional mechanism, rapid adenosine receptor desensitization may contribute to acute neuroprotective as is seen following chronic A3 receptor agonism [80].

Neuroprotection that develops over a period of several hours or days and requires new protein synthesis is termed delayed preconditioning. As in acute preconditioning, adenosine may play a role in delayed preconditioning. ATP diphosphohydrolase and 5’-nucleotidase, two enzymes involved in the local production of adenosine from ATP via hydrolysis, show enhanced activity in the CA1 region of the hippocampus following brief ischemia. This increase in enzymatic activity correlates with protection in the CA1 region from subsequent ischemic injury, given 48 hours later. Adenosine receptor blockade blocks tolerance to ischemia induced by preconditioning. As with acute preconditioning, the neuroprotective effects of ischemic preconditioning are attenuated with the administration of the selective A1 agonist DPCPX at the time of conditioning ischemia [49, 116]. Interestingly, DPCPX administered at the time of ischemia, 72 hours after preconditioning, does not reverse protection, implying a role for A1 receptors during conditioning ischemia [116].

Unmethylated cytosine-guanine rich oligonucleotides (CpG ODNs), which act on Toll-like receptor 9 (TLR9), have been shown to be a highly effective means of prophylactic neuroprotection in a mouse model of cerebral ischemia [101]. The delayed neuroprotection afforded by CpG ODNs occurs following systemic injection. CpG ODNs also confer protection from oxygen-glucose deprivation in mixed cortical cultures in vitro. Similar finding have been previously reported for the TLR4 agonist LPS [96]. An increase in systemic levels of TNF-α is required for neuroprotection in both
LPS- and CpG-mediated preconditioning [96, 101]. Interestingly, proinflammatory cytokines such as TNF-α increase the expression and signaling of A1 receptors in the brain [7]. Upregulation of A1 receptors in the CNS, effectively preparing the brain for ischemic insult, may be one mechanism by which TLR agonists elicit endogenous neuroprotection. TNF-α also upregulates A2A and A2B receptor expression on endothelial cells, which may contribute to suppression of inflammation following ischemic injury [73, 100]. This contribution may be highly relevant, as stimulation of these receptors on vascular endothelial cells suppresses expression of adhesion molecules such as E-selectin and vascular cell adhesion molecule (VCAM-1) [13]. Stimulation of excitatory A2A receptors enhances nitric oxide release and vasodilation [86], and stimulation of A2B receptors leads to expression of angiogenic factors [33]. TNF-α also leads to the upregulation of A2A receptors on peripheral immune cells [56]. Upregulation of A2A receptors on neutrophils is seen following stimulation with TNF-α, which may reduce the damage caused by inflammatory immune infiltrate into the brain following stroke [36]. With these specific adenosine receptors increased, immune cells may be more likely to produce an anti-inflammatory response in the setting of stroke especially when in conjunction with increased production of adenosine. In support of this idea, A2A receptors have been shown to decrease TNF-α production and adhesion molecule expression following stimulation with TLR4 agonists [41], which are also released endogenously following stroke [67]. Indeed, synergism between adenosine and TLRs are well documented, especially in peripheral immune cells [66, 77, 88]. While the involvement of adenosine receptors in TLR-mediated preconditioning has not been confirmed, direct regulation of adenosine-related gene products is also seen via microarray analysis in both brain and blood following TLR-mediated preconditioning (Stenzel-Poore lab, unpublished observation). For a more extensive discussion of TLR signaling in endogenous neuroprotection and stroke, please see the 2009 review by Marsh, B. J. et al. [67]. A greater understanding of the role of adenosine in endogenous neuroprotection may lead to interventions and therapeutic strategies useful in ischemia. A focus on the interaction between TLRs and adenosine receptors in preconditioning may be appropriate because systemic TNF-α levels may remain lower—a feature that is preferable in the treatment of patients.

CONCLUSION AND PERSPECTIVE

Stroke is a leading cause of death and disability in the United States [74]. Despite years of study, there is only one clinical therapy for the treatment of stroke—removal of thrombus mechanically or via lysis by administration of tissue plasminogen activator (tPA) [79]—and tPA is, at best, an imperfect treatment. Thrombolysis is only applicable in the setting of occlusive stroke, treatment must be applied within a short time window, and the risk for hemorrhagic episodes following tPA are high [26]. Though no adenosine-based therapies for treatment of stroke exist, selective activation and inhibition of adenosine receptors in the CNS, especially when combined with peripheral immune modulation, is a promising target for future stroke therapies. Perhaps the most benefit will be gained through the use of prophylactic therapies that alter the expression of adenosine receptors on specific cell types. Utilization of complementary molecules, such as prophylactic TLR-agonists, will also improve stroke treatment by enhancing the benefits of adenosine receptor stimulation. The future success of stroke therapy does not rest on the discovery of a novel miracle compound, but on the intelligent design of multimodal, synergistic treatments that target several sources of damage.

REFERENCES

[1] Abbracchio, M.P., Cattabeni, F. (1999) Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann. N. Y. Acad. Sci., 890, 79-92.
[2] Abbresato, T.J., Davis, T.P. (1999) Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J. Pharmacol. Exp. Ther., 289, 668-675.
[3] Akaiba, K., Akashi, H., Harada, H., Sakashita, H., Hiromatsu, S., Kano, T., Aoyagi, S. (2006) Moderate cerebral venous congestion induces rapid cerebral protection via adenosine A1 receptor activation. Brain Res., 1122, 47-55.
[4] Azzimondi, G., Bassein, L., Fiorani, L., Nonino, F., Montaguti, U., Celin, D., Re, G., D'Alessandro, R. (1997) Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment. Stroke, 28, 537-542.
[5] Barone, F.C., Arvin, B., White, R.F., Miller, J.A., Webb, C.L., Willette, R.N., Lynko, P.G., Feuerstein, G.Z. (1997) Tumor Necrosis Factor α: A mediator of focal ischemic brain injury. Stroke, 28, 1233-1244.
[6] Betz, A.L., Keep, R.F., Beer, M.E., Ren, X.D. (1994) Blood-brain barrier permeability and brain concentration of sodium, potassium, and chloride during focal ischemia. J. Cereb. Blood Flow Metab., 14, 29-37.
[7] Biber, K., Luhrich, B., Fiebich, B.L., Boddeke, H.W., van Calker, D. (2001) Interleukin-6 enhances expression of adenosine A1 receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. Neuropharmacology, 24, 86-96.
[8] Bjorklund, O., Shang, M., Tonazzini, I., Dare, E., Fredholm, B.B. (2008) Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. Eur. J. Pharmacol., 596, 6-13.
[9] Boison, D. (2005) Adenosine and epilepsy: from therapeutic rationales to new therapeutic strategies. Neuroscientist, 11, 25-36.
[10] Boison, D. (2006) Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol. Sci., 27, 652-658.
[11] Bond, R., Ristem, K., Shearman, C.P., Rothwell, P.M. (2004) Time trends in the published risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Cerebrovasc. Dis., 18, 37-46.
[12] Bouma, M.G., Jeunhomme, T.M., Boyle, D.L., Dentener, M.A., Voitenok, N.N., van den Wildenberg, F.A., Buurman, W.A. (1997) Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J. Immunol., 158, 5400-5408.
[13] Bouma, M.G., van den Wildenberg, F.A., Buurman, W.A. (1996) Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol., 270, C922-529.
[14] Bshesh, K., Zhao, B., Spight, D., Biaggioni, I., Feokistov, I., Denenberg, A., Wong, H.R., Shanley, T.P. (2002) The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J. Leukoc. Biol., 72, 1027-1036.
[15] Buceri, J., Gummert, J.F., Borger, M.A., Walthier, T., Doll, N., Onnasch, J.F., Metz, S., Falk, V., Mohr, F.W. (2003) Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann. Thorac. Surg., 75, 472-478.
[16] Cassidy, D.C., Tribble, C.G., Long, S.M., Laubach, V.E., Kaza, A.K., Linden, J., Nguyen, B.N., Rieger, J.M., Fiser, S.M., Kron, I.L., Kern, J.A. (2002) Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. J. Vasc. Surg., 35, 994-998.
[17] Cassidy, D.C., Tribble, C.G., Young, J.S., Gangemi, J.J., Gohari, A.R., Butler, P.D., Rieger, J.M., Kron, I.L., Linden, J., Kern, J.A.
Adenosine and Stroke

(2002) Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J. Trauma, 53, 225-229; discussion 229-231.

[18] Chen, G.J., Harvey, B.K., Shen, H., Chou, J., Victor, A., Wang, Y. (2006) Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J. Neurosci., 84, 1848-1855.

[19] Chen, H., Yang, D., Carroll, S.H., Eltzschig, H.K., Ravid, K. (2009) Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp. Hematol., 37, 533-538.

[20] Chen, J.F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M.A., Fink, J.S., Schwarzschild, M.A. (1999) A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci., 19, 9192-9200.

[21] Chen, Y., Corrden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinker, Nagel, A., Nizet, V., Insel, P.A., Junger, W.G. (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science, 314, 1792-1795.

[22] Clark, A.N., Youkey, R., Liu, X., Jia, L., Blatt, R., Day, J.Y., Sullivan, G.W., Linden, J., Tucker, A.L. (2007) A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ. Res., 101, 1130-1138.

[23] Cunha, F.Q., Assreuy, J., Moss, D.W., Rees, D., Leal, L.M.C., Moncada, S., Carrier, M., O'Donnell, C.A., Liew, F.Y. (1994) Differential induction of nitric oxide synthase in various organs of the mouse during endotoxemia: role of TNF-a and IL-1-b. Immunology, 81, 211-215.

[24] Cunha, R.A. (2005) Neuroprotection by adenosine in the brain: From A(1) receptor activation to A(2A) receptor blockade. Purin. Signal., 1, 111-134.

[25] Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.F., Enjyoji, K., Linden, J., Oukka, M., Kuchroo, V.K., Strom, T.B., Rode, I., Goldstein, A.E., Ryzhov, S., Zeng, D., Belardinelli, P., Borea, P.A. (2007) Differential expression of adenosine receptors in human monocytes and T cells. Int. J. Oncol., 31, 1383-1389.

[26] Dirnagl, U., Kitagawa, H., Mori, A., Shimada, J., Mitsumoto, Y., Kikuchi, T. (2003) Incidence and Prevalence: Hypothesis and Etiology of Neurological Diseases. In John I.G., Ira M.G., (Eds.) 2nd ed. Ralph Snyderman. Raven Press: NY, New York, 1426-1431.

[27] Dvorak, C., Kitaeva, H., Yip, L., Tankova, S., Borea, P.A. (2007) Adenosine and Stroke. Current Neuropharmacology, 5, 197-205.

[28] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[29] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[30] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[31] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[32] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[33] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[34] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[35] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[36] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[37] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[38] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.

[39] Eagles, M., Huxley, A., Perutz, M. (1966) The mechanism of muscle contraction. Nature, 211, 114-119.
come after transient focal ischemia in rats. *Neuropharmacology*, 24, 317-323.

Kobayashi, T., Nakamura, M., Nakamura, K., Katayama, Y., Abe, K. (1999) Adenosine-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats. *J. Cereb. Blood Flow Metab.*, 19, 1336-1344.

Klinger, M., Freissmuth, M., Nanoff, C. (2002) Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. *Cell Signal.*, 14, 99-108.

Kobayashi, T., Yamada, T., Okada, Y. (1998) The levels of adenosine and its metabolite in the guinea pig and rat brain during complete ischemia-in vivo study. *Brain Res.*, 787, 211-219.

Lodge, P., Cicala, C., Adcock, I.M. (2006) IL-10 induces nodulosis in rheumatoid arthritis. *Arthritis Rheum.*, 54, 1308-1315.

Liu, Y., Xiong, L., Chen, S., Wang, Q. (2006) Isoflurane tolerance by human monocytes. *Brain Res. Bull.*, 68, 14-18.

Linden, J. (2006) Mouse spinal cord compression injury is reduced by the proximal promoter. *J. Cereb. Blood Flow Metab.*, 26, 1-5.

Liu, T., Jiang, Y., Li, Y., Pham, A., Liao, L., Kern, J.A. (2006) Monopoli, A., Lozza, G., Forlani, A., Mattavelli, A., Ongini, E. (2006) Rapid tolerance to focal cerebral ischemia in rats is attenuated by adenosine A1 receptor antagonist. *J. Cereb. Blood Flow Metab.*, 22, 161-170.

Nakamura, T., Cronberg, T., Ryttter, A., Asztely, F., Fredholm, B.B., Smith, M.L., Wieloch, T. (2004) Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. *Eur. J. Neurosci.*, 20, 1197-1204.

Oral, M., Fisher, M. (1997) Acute ischemic stroke therapy. A clinical overview. *Eur. Neurol.*, 38, 141-154.

Palmer, T.M., Benovic, J.L., Stiles, G.L. (1995) Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. *J. Biol. Chem.*, 270, 29607-29613.

Parnidge, W.M., Yoshikawa, T., Kang, Y.S., Miller, L.P. (1994) Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. *J. Pharmacol. Exp. Ther.*, 268, 14-18.

Pearson, T., Damian, K., Lysak, R.E., Frenguelli, B.G. (2006) Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. *J. Neurochem.*, 97, 1357-1368.

Phillis, J.W. (1995) The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. *Brain Res.*, 705, 79-88.

Picano, E., Abbraccchio, M.P. (2000) Adenosine, the imperfect endogenous anti- ischemic- cardio- neuroprotector. *Brain Res. Bull.*, 52, 75-82.

Pignataro, G., Simon, R.P., Boisdon, D. (2007) Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. *J. Cereb. Blood Flow Metab.*, 27, 1-5.

Pober, J.S., Sessa, W.C. (2007) Evolving functions of endothelial cells in inflammation. *Nat. Rev. Immunol.*, 7, 803-815.

Pugliese, A.M., Coppi, E., Volpini, R., Cristalli, G., Corradetti, R., Leong, L.S., Jacobson, K.A., Pedata, F. (2007) Role of adenosine A3 receptors on CA1 hippocampal neuroprotection. *Am. J. Pathol.*, 171, 1774-1788.

Ribeiro, J.A. (2005) What can adenosine neuromodulation do for neuroprotection? *Curr. Drug Target CNS Neurol. Disord.*, 4, 1788.

Ramakers, B.P., Rijksen, N.P., Rongen, G.A., van der Hoeven, J.G. (2006) Role of adenosine A1 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. *Biochem. Pharmacol.*, 74, 768-779.

Reece, T.R., Okonkwo, D.O., Ellman, P.L., Maxey, T.S., Tache, M., Kharenko, S.L. (1999) Adenosine promotes neutrophil chemotaxis. *Arthritis Rheum.*, 42, 502-510.
Adenosine and Stroke

(2007) Endotoxin preconditioning protects against the cytotoxic effects of TNFα after stroke: a novel role for TNFα in LPS-ischemic tolerance. J. Cereb. Blood Flow Metab., 27, 1636-1674.

[97] Sebastiao, A.M., de Mendonca, A., Moreira, T., Ribeiro, J.A. (2001) Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J. Neurosci., 21, 8564-8571.

[98] Sheardown, M.J., Knutsen, L.I.S. (1996) Unexpected neuroprotection observed with the adenosine A2A receptor agonist CGS 21680. Drug Dev. Res., 39, 108-114.

[99] Spera, P.A., Ellison, J.A., Feuerstein, G.Z., Barone, F.C. (1998) Delayed treatment with an adenosine A2A receptor agonist and antagonist promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood, 111, 251-259.

[100] St Hilaire, C., Koupenova, M., Carroll, S.H., Smith, B.D., Ravid, K. (2008) Regulation of A(2A) adenosine receptor expression and functioning following permanent focal cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. J. Cereb. Blood Flow Metab., 287, 295-302.

[101] Vons, C.F. (2004) Selective inactivation or reconstitution of adenosine A1 receptor expression in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med., 10, 1081-1087.

[102] Wittk-Sarsat, V., Rieu, P., Descomps-Latscha, B., Lesavre, P., Halbachs-Mecarelli, L. (2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest., 80, 617-673.

[103] Takahashi, H.K., Iwagaki, H., Hamano, R., Kanke, T., Liu, K., Sadamori, H., Yagi, T., Yoshino, T., Sendo, T., Tanaka, N., Nishibori, M. (2007) Effect of adenosine receptor subtype stimulation on mixed lymphocyte reaction. Eur. J. Pharmacol., 564, 204-210.

[104] Tatsilimak, T., Takano, K., Carano, R.A., Miller, L.P., Foster, A.C., Fisher, M. (1998) Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke, 29, 1952-1958.

[105] Trincavelli, M.L., Melani, A., Guidi, S., Cuboni, S., Cipriani, S., Pedata, F., Martini, C. (2008) Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain. J. Neurochem., 104, 479-490.

[106] Trincavelli, M.L., Tuscano, D., Marroni, M., Falleni, A., Gremigni, V., Ceruti, S., Abbracchio, M.P., Jacobson, K.A., Cattabeni, F., Martini, C. (2002) A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. Mol. Pharmacol., 62, 1373-1384.

[107] von Lubitz, D.K. (1999) Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol., 371, 85-102.

[108] von Lubitz, D.K., Lin, R.C., Jacobson, K.A. (1995) Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. J. Cereb. Blood Flow Metab., 287, 295-302.

[109] Adenosine A3 receptor and stimulation cerebral ischemia. Eur. J. Pharmacol., 263, 59-67.

[110] von Lubitz, D.K., Ye, W., McClellan, J., Lin, R.C. (1999) Stimulation of adenosine A3 receptors in cerebral ischemia. Neuronal death, recovery, or both? Ann. N. Y. Acad. Sci., 890, 93-106.

[111] Welbourn, C.R., Goldman, G., Paterson, I.S., Valeri, C.R., Shepro, D., Hechtman, H.B. (1991) Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br. J. Surg., 78, 651-655.

[112] Wilz, A., Pritchard, E.M., Li, T., Lan, J.Q., Kaplan, D.L., Boisson, D. (2008) Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials, 29, 3669-3676.

[113] Yamao, H., Chino, M., Yamori, Y. (2007) Adenosine induces expression of glial cell line-derived neurotrophic factor (GDNF) in primary rat astrocytes. Neurosci. Res., 59, 467-474.

[114] Yang, D., Zhang, Y., Nguyen, H.G., Koupénova, M., Chauhan, A.K., Makitalo, M., Jones, M.R., St Hilaire, C., Seldin, D.C., Toselli, P., Lamperti, E., Schreiber, B.M., Gavras, H., Wagner, D.D., Ravid, K. (2006) The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest., 116, 1913-1923.

[115] Yoshida, N., Nakanuma, K., Kuriyama, Y., Matsumoto, M., Sakabe, T. (2004) Adenosine A(1) receptor antagonist and mitochondrial ATP-sensitive potassium channel blocker attenuate the tolerance to focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab., 24, 771-779.

[116] Yu, L., Huang, Z., Mariani, J., Wang, Y., Moskovitz, M., Chen, J.F. (2004) Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med., 10, 1081-1087.

[117] Zarek, P.E., Huang, C.T., Lutz, E.R., Kowalski, J., Horton, M.R., Linden, J., Drake, C.G., Powell, J.D. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood, 111, 251-259.